← Human Trials & Peer-Reviewed Studies
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
Plain-language guide to PMID 16052083 (2005): double-blind randomized controlled trial study of GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 16052083
- Journal
- AIDS (London, England)
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Falutz J et al. (11 authors)
- DOI
- 10.1097/01.aids.0000180099.35146.30
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.
To investigate the effects of TH9507, a novel growth hormone releasing factor, on abdominal fat accumulation, metabolic and safety parameters in HIV-infected patients with central fat accumulation.
Who Took Part
PubMed indexes the participants as teenagers, adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got GHRH (Growth Hormone-Releasing Hormone) and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received GHRH (Growth Hormone-Releasing Hormone).
Some participants received a placebo instead of GHRH (Growth Hormone-Releasing Hormone), giving a reference point.
The primary outcome was change in abdominal fat, assessed by dual energy X-ray absorptiometry and cross-sectional computerized tomography scan.
Secondary endpoints included change in insulin-like growth factor-I (IGF-I), metabolic, quality of life, and safety parameters.
What Was Measured
Topics PubMed links to this paper include Abdomen, Adipose Tissue, Growth Hormone-Releasing Hormone, HIV Infections, HIV-Associated Lipodystrophy Syndrome, Insulin-Like Growth Factor I and Peptides.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of GHRH (Growth Hormone-Releasing Hormone).
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (AIDS (London, England)), a journal based in England.
More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compound
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.